Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E57.98 EPS (ttm)2.11 Insider Own0.40% Shs Outstand224.00M Perf Week2.57%
Market Cap27.35B Forward P/E18.60 EPS next Y6.57 Insider Trans213.76% Shs Float223.64M Perf Month24.98%
Income476.80M PEG3.21 EPS next Q1.25 Inst Own96.90% Short Float1.79% Perf Quarter3.02%
Sales3.25B P/S8.41 EPS this Y162.90% Inst Trans-2.70% Short Ratio1.28 Perf Half Y-3.99%
Book/sh39.54 P/B3.09 EPS next Y23.61% ROA- Target Price155.00 Perf Year9.13%
Cash/sh6.53 P/C18.71 EPS next 5Y18.07% ROE- 52W Range96.18 - 145.41 Perf YTD-0.20%
Dividend- P/FCF- EPS past 5Y14.00% ROI4.20% 52W High-14.14% Beta1.44
Dividend %- Quick Ratio2.80 Sales past 5Y31.50% Gross Margin91.80% 52W Low29.82% ATR4.10
Employees3121 Current Ratio3.30 Sales Q/Q24.10% Oper. Margin- RSI (14)62.45 Volatility3.11% 3.02%
OptionableYes Debt/Eq0.34 EPS Q/Q85.20% Profit Margin- Rel Volume0.61 Prev Close122.11
ShortableYes LT Debt/Eq0.32 EarningsJul 27 BMO Payout- Avg Volume3.12M Price124.86
Recom1.90 SMA2011.73% SMA507.80% SMA2001.58% Volume1,098,821 Change2.25%
May-25-17Upgrade Morgan Stanley Equal-Weight → Overweight
May-23-17Downgrade JP Morgan Overweight → Neutral
Mar-30-17Initiated UBS Buy $138
Mar-02-17Initiated Instinet Buy $148
Feb-17-17Reiterated RBC Capital Mkts Outperform $187 → $177
Dec-22-16Reiterated RBC Capital Mkts Outperform $188 → $187
Dec-15-16Initiated Oppenheimer Perform
Dec-13-16Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-03-16Initiated Deutsche Bank Buy $164
Oct-28-16Upgrade Goldman Neutral → Buy
Oct-28-16Upgrade FBR & Co. Underperform → Mkt Perform $92 → $130
Oct-28-16Reiterated Wedbush Neutral $132 → $135
Sep-23-16Initiated Wedbush Neutral $132
Sep-16-16Reiterated FBR & Co. Underperform $82 → $92
Sep-15-16Initiated FBR & Co. Underperform $82
Jul-29-16Reiterated Stifel Buy $195 → $182
Jul-29-16Reiterated Barclays Equal Weight $165 → $150
Jul-13-16Reiterated SunTrust Buy $220 → $197
Jul-13-16Initiated RBC Capital Mkts Outperform $188
Jul-11-16Upgrade Credit Suisse Neutral → Outperform $186 → $165
Jun-28-17 12:39PM  Where to find value in health-care stocks ahead of Senate... CNBC Videos
Jun-27-17 04:24PM  Here's Why Ra Pharmaceuticals Inc. Tumbled as Much as 32% Today Motley Fool
Jun-26-17 07:26AM  3 Top Stocks on Sale This Summer Motley Fool
Jun-23-17 08:00AM  Alexion Receives Positive CHMP Opinion for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG) in the European Union Business Wire
Jun-21-17 02:18PM  Biotech Insider Just Loaded Up $234 Million Worth the Stock TheStreet.com
12:05PM  Here are the biotech stocks the traders are buying CNBC Videos
10:35AM  Amgen: In Defense of A Pipeline Barrons.com
08:00AM  Today's Research Reports on Stocks to Watch: Regeneron Pharmaceuticals and Alexion Pharmaceuticals Accesswire
07:57AM  Food & pharma in the trader blitz CNBC Videos
Jun-20-17 01:03PM  UPDATE: Alexion Pharma: Its CEO Really Likes Its Stock! Barrons.com
11:36AM  Story Stocks from Briefing.com Briefing.com
09:09AM  Morning Movers: Tesla Rises, Chipotle Slumps, Lennar Jumps Barrons.com
Jun-19-17 11:11AM  Biogen: "The Underperformance Stops Here" Barrons.com
Jun-16-17 04:40PM  Alexion Pharmaceuticals, Inc. Value Analysis (NASDAQ:ALXN) : June 16, 2017 Capital Cube
Jun-15-17 02:00PM  Alexion Has a Savior Complex Bloomberg
10:07AM  Company News for June 15, 2017 Zacks
08:13AM  Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALXN-US : June 15, 2017 Capital Cube
08:02AM  Why Alexion's Gain In the C-Suite Doesn't Bode Well For Biogen Takeout Prospects TheStreet.com
08:00AM  Today's Research Reports on Stocks to Watch: Epizyme and Alexion Pharmaceuticals Accesswire
12:20AM  [$$] Alexions Housecleaning Should Continue to Pay Off The Wall Street Journal
Jun-14-17 05:46PM  The Hot Stock: Alexion Pharmaceuticals Jumps 9.3% Barrons.com +9.26%
05:02PM  What Happened in the Stock Market Today Motley Fool
04:16PM  Is Defecting CFO A Glutton For Punishment By Moving To Alexion? Investor's Business Daily
04:16PM  Alexion Stock Soars After It Poaches Biogen CFO Investopedia
02:02PM  [$$] Alexion Even Stronger After Adding Biogen CFO Barrons.com
01:37PM  Alexion's New CFO Continues To Shore Up Investor Concerns Benzinga
01:31PM  One of Stephanie Link's picks jumps 10 percent CNBC Videos
12:22PM  Alexion Pops, Biogen Falls on Executive Shuffle; Epizyme Recovers As Investors Digest Phase 2 Data TheStreet.com
12:15PM  [$$] Alexion's Housecleaning Should Continue to Pay Off The Wall Street Journal
10:31AM  Biogen Loses Top Executive Again, CFO Clancy to Join Alexion Zacks
09:47AM  Stocks Flatten Ahead Of Fed, But Dow Etches New High Investor's Business Daily
09:15AM  Alexion Pharmaceuticals Adds New CFO From Biogen 24/7 Wall St.
08:31AM  Morning Movers: Alexion Climbs on Biogen Hire; H&R Block Jumps Barrons.com
08:03AM  3 Stocks to Watch on Wednesday: Ford Motor Company (F), Alexion Pharmaceuticals, Inc. (ALXN) and H & R Block Inc (HRB) InvestorPlace
Jun-13-17 06:05PM  Biogen CFO Bolts to Alexion TheStreet.com
05:46PM  Alexion names Biogen's Paul Clancy as CFO Reuters
05:05PM  Biogen exodus continues as CFO set to join Alexion American City Business Journals
04:45PM  Alexion hires Biogen executive to serve as its CFO MarketWatch
04:30PM  Alexion Names Paul Clancy Chief Financial Officer Business Wire
Jun-07-17 05:52AM  [$$] Alexion: A High Risk but Very High Reward Stock Barrons.com
Jun-03-17 09:01AM  3 Stocks With Vertex Pharmaceuticals-Like Return Potential Motley Fool
Jun-02-17 10:33AM  Alexion stock rises 1.4% after naming new executives MarketWatch
Jun-01-17 04:10PM  Alexion Announces Additions to Executive Leadership Team Business Wire
11:12AM  Small-Cap Action Is Improving TheStreet.com
07:37AM  Analysts Views on Alexion Pharmaceuticals and Its Peers Market Realist
07:37AM  Healthcare Companies Analyst Ratings: May 2226, 2017 Market Realist
06:37AM  Why Is Alexion (ALXN) Down 23% Since the Last Earnings Report? Zacks
May-31-17 05:05PM  Strensiq: Key Growth Driver for Alexion Pharmaceuticals in 2017 Market Realist
03:35PM  Soliris Is Expected to Continue Generating High Revenue Market Realist
01:38PM  What to Expect from Alexion Pharmaceuticals in 2017 Market Realist
12:01PM  Top Losers in the Healthcare Sector: May 2226, 2017 Market Realist
09:54AM  Biotech Stocks Feel the Pain: Time to Buy? Barrons.com
May-30-17 02:51PM  Analyst: With This Much Pessimism Priced In, Alexion Begins To Look Attractive Benzinga
01:43PM  Lifshitz & Miller LLP Announces Investigation of Akari Therapeutics, Plc, Alexion Pharmaceuticals, Inc., Amgen Inc., Cel-Sci Corp., Dick's Sporting Goods, Inc., Eco Science Solutions, Inc., Intra-Cellular Therapies, Inc. and Twilio Inc. PR Newswire
10:44AM  Alexion Pharma: Negative Market Sentiment Creates Buying Opportunity TheStreet.com
10:00AM  Alexion to Present at Upcoming Investor Conferences Business Wire
May-29-17 01:00AM  The Good, the Bad and the Ugly; Explaining the Inexplicable: Doug Kass' Views TheStreet.com
May-25-17 10:38AM  2 Key Reasons Morgan Stanley Upgraded Alexion Pharmaceuticals Benzinga
09:52AM  Alexion Pharmaceuticals: Time to Buy? Barrons.com
09:00AM  The Market In 5 Minutes Benzinga
07:36AM  Analysts' Actions -- Kellogg, Kraft Heinz, Altria, PayPal and More TheStreet.com
May-24-17 10:55AM  Alexion Pharmaceuticals: Waiting For the Next Shoe? Barrons.com
10:10AM  Company News for May 24, 2017 Zacks
07:00AM  Trader's Daily Notebook: As Long Weekend Nears, Volume Will Stay Low TheStreet.com
04:00AM  When the Patient Is a Gold Mine: The Trouble With Rare-Disease Drugs Bloomberg
May-23-17 05:50PM  Alexion Shares Drop Amid Executive Changes TheStreet.com -9.34%
05:11PM  Biotech And Pharma Industry And Stock News Investor's Business Daily
05:00PM  Why Herbalife, Alexion Pharmaceuticals, and Brown-Forman Slumped Today Motley Fool
04:24PM  Alexion At Nearly 4-Year Low After Announcing Exits Of 4 Execs Investor's Business Daily
03:05PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexion Pharmaceuticals, Inc. (ALXN) PR Newswire
01:43PM  [$$] Alexion's Shakeup Continues as Four Executives Exit The Wall Street Journal
01:17PM  What To Make Of the Alexion Shake-up Investopedia
01:11PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alexion Pharmaceuticals, Inc. - ALXN PR Newswire
12:42PM  Alexions top management shake-up includes CFO who started in December MarketWatch
12:24PM  BMO: Too Early to Tell If Alexion's Management Shakeup Bodes Well for Stock TheStreet.com
12:18PM  Here's Why Alexion Pharma (ALXN) Stock is Sinking Today Zacks
12:01PM  Alexion stock plummets 9% after top management shake-up MarketWatch
11:53AM  Alexion: Look Out Below! Barrons.com
09:29AM  Biotech Movers: Cerus, Alexion, NantKwest TheStreet.com
08:00AM  Alexion Announces Executive Leadership Changes Business Wire
May-21-17 05:08PM  Stocks That Fell to 3-Year Lows in the Week of May 19 GuruFocus.com
May-19-17 04:30PM  Amgen, Gilead, Biogen Won't Lead The Biotech Boom So Who Will? Investor's Business Daily
01:09PM  5 Reasons Big Biotech Could Gain 25%-30% Barrons.com
12:02PM  Why Stay Bullish On Gilead Barrons.com
May-18-17 07:00PM  For millions of Chinese with rare diseases, some relief in sight Reuters
06:51PM  Cramer's lightning round: It's OK to own this stock as long as you're diversified CNBC
10:30AM  Glancy Prongay & Murray LLP Commences Investigation on Behalf of Alexion Pharmaceuticals, Inc. Investors Business Wire
May-17-17 05:55PM  Alexion's (ALXN) Strensiq Results Positive in Long-Term Study Zacks
12:03PM  Here's Why Omeros Corporation Is Surging Again Today Motley Fool
May-16-17 12:01PM  Moderna Can't Escape My Intellectual Property, Says Arbutus CEO Forbes
08:04AM  3 Top Healthcare Stocks to Buy Now Motley Fool
06:30AM  Rady Childrens Institute for Genomic Medicine and Alexion Pharmaceuticals Partner to Speed the Diagnosis of Rare Genetic Disorders in Newborns Business Wire
May-15-17 08:00AM  Long-term Data Confirm Benefits of Treatment with Strensiq® (asfotase alfa) in Adolescents and Adults with Hypophosphatasia (HPP) Through Five Years Business Wire
May-11-17 09:07AM  ALXN1210 Is Expected to Boost Alexion Pharmaceuticals Revenue Market Realist
08:59AM  Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALXN-US : May 11, 2017 Capital Cube
07:36AM  Alexion Pharmaceuticals Has Raised Its 2017 Earnings Guidance Market Realist
06:30AM  Alexion Global Headquarters Earns Highest LEED® Green Building Certification Business Wire
May-10-17 02:35PM  New Patient Starts Expected to Drive Soliriss Revenue in 2017 Market Realist
01:05PM  Alexion Pharmaceuticals Projects Robust 2017 Revenue Performance Market Realist
11:09AM  Analysts Latest Recommendations for Alexion and Its Peers Market Realist
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COUGHLIN CHRISTOPHER JDirectorJun 15Buy117.102,000234,2006,333Jun 16 04:55 PM
BAKER BROS. ADVISORS LPDirectorJun 15Buy117.33656,38777,012,4917,645,906Jun 16 04:04 PM
PARVEN ALVIN SDirectorJun 15Sale116.7883597,5117,568Jun 16 04:54 PM
BAKER BROS. ADVISORS LPDirectorJun 14Buy116.321,348,955156,915,4447,317,906Jun 16 04:03 PM
BAKER BROS. ADVISORS LPDirectorJun 14Buy118.004,392518,2567,321,850Jun 16 04:04 PM
HANTSON LUDWIGCEOJun 14Buy116.7210,0001,167,20038,725Jun 19 05:21 PM
O'Neill JulieEVP. Global OperationsMar 02Sale133.8065187,10437,864Mar 06 06:03 PM
Moriarty John BEVP & General CounselMar 01Sale132.5028237,36544,672Mar 01 07:46 PM
MACKAY MARTINEVP & Global Head of R&DMar 01Sale132.5037049,02550,688Mar 01 07:45 PM
BELL LEONARDDirectorMar 01Sale132.501,240164,300390,670Mar 01 07:44 PM
Wagner Heidi LSVP, Global Government AffairsMar 01Sale132.5015620,67029,010Mar 01 07:44 PM
Carmichael ClareEVP, Chief HR OfficerMar 01Sale132.5040453,53039,161Mar 01 07:44 PM
Moriarty John BEVP & General CounselFeb 28Sale131.71910119,85644,954Mar 01 07:46 PM
MACKAY MARTINEVP & Global Head of R&DFeb 28Sale131.7062582,31338,258Mar 01 07:45 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 28Sale131.7033043,46114,884Mar 01 07:45 PM
O'Neill JulieEVP. Global OperationsFeb 28Sale131.7066487,44931,015Mar 01 07:46 PM
BELL LEONARDDirectorFeb 28Sale131.712,738360,622391,910Mar 01 07:44 PM
Wagner Heidi LSVP, Global Government AffairsFeb 28Sale131.7048063,21629,166Mar 01 07:44 PM
Carmichael ClareEVP, Chief HR OfficerFeb 28Sale131.71915120,51533,065Mar 01 07:44 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 28Sale131.013,783495,61133,860Mar 06 06:03 PM
Moriarty John BEVP & General CounselFeb 27Sale131.2061280,29445,864Mar 01 07:46 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 27Sale131.20719,31530,197Mar 01 07:45 PM
MACKAY MARTINEVP & Global Head of R&DFeb 27Sale131.20860112,83238,883Mar 01 07:45 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 27Sale131.2026034,11215,214Mar 01 07:45 PM
O'Neill JulieEVP. Global OperationsFeb 27Sale131.20910119,39231,679Mar 01 07:46 PM
Wagner Heidi LSVP, Global Government AffairsFeb 27Sale131.2035846,97029,646Mar 01 07:44 PM
Carmichael ClareEVP, Chief HR OfficerFeb 27Sale131.20860112,83233,980Mar 01 07:44 PM
BELL LEONARDDirectorFeb 09Sale126.8424631,203394,648Feb 10 06:05 PM
Moriarty John BEVP & General CounselFeb 09Sale126.8416721,18246,476Feb 10 06:05 PM
MACKAY MARTINEVP & Global Head of R&DFeb 09Sale126.8421727,52439,743Feb 10 06:05 PM
Carmichael ClareEVP, Chief HR OfficerFeb 09Sale126.8416721,18234,840Feb 10 06:05 PM
Moriarty John BEVP & General CounselFeb 07Sale128.0913517,29246,643Feb 08 04:40 PM
Carmichael ClareEVP, Chief HR OfficerFeb 07Sale128.0916621,26335,007Feb 08 04:40 PM
BELL LEONARDDirectorFeb 07Sale128.091,010129,371394,894Feb 08 04:40 PM
Wagner Heidi LSVP, Global Government AffairsFeb 07Sale128.0922228,43630,004Feb 08 04:38 PM
Moriarty John BEVP & General CounselFeb 06Sale125.693,403427,73946,778Feb 08 04:40 PM
O'Neill JulieEVP. Global OperationsFeb 06Sale125.692,795351,30432,589Feb 08 04:40 PM
Carmichael ClareEVP, Chief HR OfficerFeb 06Sale125.703,404427,87235,173Feb 08 04:40 PM
MACKAY MARTINEVP & Global Head of R&DFeb 06Sale125.702,728342,90439,960Feb 08 04:39 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 06Sale125.6916520,73930,268Feb 08 04:39 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 06Sale125.701,045131,35715,474Feb 08 04:39 PM
BELL LEONARDDirectorFeb 06Sale125.697,715969,728395,904Feb 08 04:40 PM
Wagner Heidi LSVP, Global Government AffairsFeb 06Sale125.691,710214,93530,226Feb 08 04:38 PM
BELL LEONARDDirectorJan 10Option Exercise22.901002,290403,719Jan 13 04:36 PM
BELL LEONARDDirectorJan 10Sale144.9910014,499403,619Jan 13 04:36 PM
BELL LEONARDDirectorJan 09Option Exercise22.904,853111,134408,472Jan 09 05:21 PM
BELL LEONARDDirectorJan 09Sale144.9033448,397403,285Jan 09 05:21 PM
BELL LEONARDDirectorJan 09Sale144.934,853703,345403,619Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Option Exercise54.2620,1661,094,30426,539Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Option Exercise22.9034,210783,409438,497Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Sale137.4066891,783403,619Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Sale137.5334,2104,704,730404,287Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Sale136.862,493341,2023,880Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Sale138.5420,1662,793,7526,373Jan 09 05:21 PM
Moriarty John BEVP & General CounselDec 12Sale118.611,044123,82950,181Dec 13 06:24 PM
Thiel CarstenEVP, Chief Commercial OfficerDec 09Sale130.002,308300,04030,433Dec 13 06:24 PM
Wagner Heidi LSVP, Global Government AffairsNov 14Sale115.10596,79131,936Nov 16 06:00 PM
BELL LEONARDDirectorNov 04Option Exercise22.9036,649839,262440,936Nov 07 07:44 PM
BELL LEONARDDirectorNov 04Sale142.4066895,123404,287Nov 07 07:44 PM
BELL LEONARDDirectorNov 04Sale140.3436,6495,143,377404,287Nov 07 07:44 PM
BELL LEONARDDirectorOct 31Option Exercise22.901,30029,770406,589Nov 02 07:22 PM
BELL LEONARDDirectorOct 31Sale135.3733445,214404,955Nov 02 07:22 PM
BELL LEONARDDirectorOct 31Sale135.281,300175,864405,289Nov 02 07:22 PM
Thiel CarstenEVP, Chief Commercial OfficerOct 14Sale120.284,584551,36432,741Oct 18 06:29 PM
Wagner Heidi LSVP, Global Government AffairsOct 03Sale122.4112014,68931,995Oct 05 05:25 PM
Thiel CarstenEVP, Chief Commercial OfficerOct 03Sale122.41293,55037,325Oct 05 05:25 PM
Thiel CarstenEVP, Chief Commercial OfficerSep 13Sale129.003,000387,00037,354Sep 14 04:34 PM
Thiel CarstenEVP, Chief Commercial OfficerSep 12Sale124.2022527,94540,354Sep 14 04:34 PM
Miller EdwardSVP, Chief Compliance OfficerSep 09Sale128.3236747,09316,519Sep 09 06:23 PM
Thiel CarstenEVP, Chief Commercial OfficerSep 06Sale125.941,000125,94040,579Sep 08 04:33 PM
O'Neill JulieEVP. Global OperationsSep 02Sale126.2965082,08935,384Sep 02 05:11 PM
Carmichael ClareEVP, Chief HR OfficerAug 30Sale127.761,000127,76038,577Sep 01 04:57 PM
PARVEN ALVIN SDirectorAug 22Option Exercise18.0115,000270,15021,373Aug 24 05:33 PM
PARVEN ALVIN SDirectorAug 22Sale136.5315,0002,047,9506,373Aug 24 05:33 PM
PARVEN ALVIN SDirectorAug 15Sale135.5170094,8576,373Aug 24 05:33 PM
Carmichael ClareEVP, Chief HR OfficerAug 08Sale137.1416522,62839,577Aug 10 06:23 PM
Moriarty John BEVP & General CounselAug 08Sale137.1413518,51451,225Aug 10 06:23 PM
Sinha VikasEVP & CFOAug 08Sale137.1427737,988178,463Aug 10 06:23 PM
Wagner Heidi LSVP, Global Government AffairsAug 08Sale137.1422230,44532,115Aug 10 06:24 PM
BELL LEONARDDirectorAug 08Sale137.141,010138,511405,289Aug 10 06:22 PM
Hallal DavidCEOAug 08Sale137.1433245,530189,266Aug 10 06:22 PM